Navigation Links
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Date:12/14/2008

rous tactile or painful stimulation was 7/183 (4%) for colonoscopy and 24/149 (16%) for bronchoscopy. The duration of minimal or complete unresponsiveness ranged from 2 to 16 minutes in colonoscopy patients and from 2 to 20 minutes in bronchoscopy patients.

The use of supplemental oxygen is recommended in all patients receiving LUSEDRA. Airway assistance maneuvers may be required. As with other sedative-hypnotic agents, LUSEDRA may produce additive cardio-respiratory effects when administered with other cardio-respiratory depressants such as benzodiazepines and narcotic analgesics. When LUSEDRA is used at greater than the recommended doses, the incidence of serious adverse reactions is increased.

The most common adverse reactions (reported in greater than 20%) are paresthesia and pruritis.

    Please see FDA-approved labeling text at
http://www.eisai.com/presskit.asp?ID=217 .

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
4. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
5. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
6. FDA Approves First Hepatitis B Viral Load Test
7. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
8. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
9. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
10. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Havel,s market leading EchoStim® Echogenic Insulated needle has ... Peripheral Nerve Blocks (PNBs) using nerve stimulation and ... improved needle has more, brighter, easier to see ... inexperienced practitioners the benefits of using both nerve ...
... 12, 2011 The association representing Montana,s providers of ... bill in Congress to repeal the controversial Medicare "competitive" ... "It is imperative that H.R. 1041 pass ... Medicare patients and local businesses in Montana," said Mike ...
Cached Medicine Technology:Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 2Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 3Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 4
(Date:4/23/2014)... Cancer Center researchers say clinical trials for a ... (AML) are very promising. Patients treated with CPX-351, ... daunorubicin, are showing better responses than patients treated ... , "Acute myeloid leukemia is an aggressive blood ... especially in older patients," explained Jeffrey Lancet, M.D., ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... Management Team and Board of Directors , ... Company,s VisionCHERRY HILL, N.J., March 18 eFoodSafety.com, Inc. ... company with a portfolio of aesthetic, dermatology, environmental and ... name from eFoodSafety.com, Inc. to Nuvilex, Inc. The Company ...
... software provider , is launching a new website. The website ... in-depth understanding of EMR-integrated services Also featured are an email ... , ... Little Rock, AR (PRWeb) March 18, 2009 ...
... EXTON, Pa., March 18 Kensey Nash Corporation (Nasdaq: ... has approved a stock repurchase. The new program allows ... of its issued and outstanding shares of Common Stock and ... the repurchases using its available cash. "Given our strong cash ...
... YORK, March 18 The Dirty Secrets ... products labeled "fragrance free" may actually contain chemicals to ... pollute the air in your home with harmful chemicals. ... about common spring cleaning hazards and how to avoid ...
... SAN FRANCISCO, March 18 The Women,s Dermatologic ... announces the 2009-2010 presidency of Wendy E. Roberts, ... Annual Meeting Luncheon held recently in conjunction with the ... Suzanne M. Connolly, MD , served as WDS ...
... Patient,s Own Stem Cells to Be Harvested and Transplanted ... Permanent Dental ImplantationRANCHO SANTA MARGARITA, Calif., March 18 ... infectious grin, but to attach an implant would be ... in his jaw. Dr. Ivan Ho, a Southern ...
Cached Medicine News:Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 2Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 3Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 4Health News:New Electronic Medical Transcription Company Website Arrives 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:Five Hot Show Ideas for Spring-Related Topics 2Health News:Wendy E. Roberts, MD, Named 2009-2010 President of the Women's Dermatologic Society 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 3
... Portex® Blue Line ULTRA® Suctionaid® tracheostomy tubes ... removal of secretions from above the tracheostomy ... ULTRA® Suctionaid® tracheostomy tubes provide an additional ... from above the tracheostomy tube cuff helping ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
... For additional patient safety, the ... an integral 15 mm ISO ... to a ventilator, with or ... place , ,Portex® laryngectomy ...
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
Medicine Products: